Compounded tirzepatide is prepared for individual patient needs; Zepbound is Lilly’s branded prescription medicine. They differ in preparation, regulatory review and product instructions. Sprout offers compounded tirzepatide from $149/month equivalent on the 12-month plan, billed upfront, with shorter plans available. This guide compares those differences and the questions to discuss with your clinician.
Research checked: October 18, 2026.
What is the difference between compounded tirzepatide and Zepbound?
The main differences are how the product is prepared, reviewed and supplied. Zepbound has its own approved labeling and clinical evidence; a compounded prescription is assessed for an individual patient. Compounded drugs are not FDA-approved. QA LABEL
| Question | Compounded tirzepatide | Zepbound |
|---|---|---|
| FDA premarket review? | No premarket review; patient-specific compounding | FDA-approved prescription product with specific labeling |
| Who supplies the product? | The dispensing compounder identified on the prescription and label | Branded product marketed by Lilly |
| Where do directions come from? | The patient’s prescription and that pharmacy’s label | The prescribed presentation and approved product instructions |
| Can branded trial results be assumed? | No | Evidence belongs to the studied branded product and population |
| What price is being compared? | Sprout’s selected prepaid plan and included care | The selected manufacturer or pharmacy medication offer |
Table prepared October 18, 2026 from FDA compounding guidance, the Zepbound label and the Sprout offer module. It is not a quality ranking of individual pharmacies. QA LABEL OFFER
Is compounded tirzepatide a generic version of Zepbound?
No. Compounded tirzepatide is a compounded preparation, not an approved generic version of Zepbound. FDA treats compounding and generic-drug approval as different processes. QA
Your clinician reviews the reason for compounding. FDA recommends compounded drugs only for patients whose medical needs cannot be met by an approved drug. FDA
How should I compare cost?
Sprout’s 12-month compounded tirzepatide offer is $149/month equivalent, with other plan lengths available. The annual plan is billed at $1,788 upfront. The cost guide lists every plan and a dated manufacturer-vial comparison, including the conditions on the lower manufacturer rates. OFFER
Compare payment timing and included care before deciding that one quote is cheaper. A medication-only price and a telehealth plan total are not the same bill.
What should I ask my clinician?
Ask which approved options fit your medical history, why a compounded preparation is being considered, and how you will receive follow-up care. Ask the pharmacist to explain the exact vial label and any measurement instructions. Do not copy a branded product’s concentration or device instructions onto a different preparation. FDA DOSE
The compounded tirzepatide guide covers the intake and pharmacy questions. The provider checklist covers clinician access, pharmacy details and billing terms.
Frequently asked questions
Are these products interchangeable?
Do not assume that they are. Ask the prescribing clinician and pharmacist about the exact product and instructions.
Can branded clinical results be used to predict compounded results?
No. This guide does not transfer branded-drug trial outcomes to a compounded preparation.
How is the Sprout annual plan billed?
The $149/month equivalent is based on $1,788 billed upfront for the 12-month plan. Shorter plans are available.
Next step
See if you qualify. Start with an online assessment. An independent licensed clinician reviews your information and decides whether to prescribe.
Sources and method
This is an educational guide, not individual prescribing advice. Sources were checked October 18, 2026. Prices are kept separate by billing period; clinical claims are limited to the cited source.
- FDA compounding questions and answers — retrieved October 18, 2026. Direct GET, 200.
- Zepbound US prescribing information, sections 1–5 and 12.1 — retrieved October 18, 2026. Direct PDF GET, 200; current retrieved label includes August 2026 revision.
- FDA concerns about unapproved GLP-1 drugs — retrieved October 18, 2026. Direct GET, 200.
- FDA dosing-error alert — retrieved October 18, 2026. Direct GET, 200.
- Sprout offer module, pinned source — retrieved October 18, 2026. Local git show origin/main; not an authenticated web fetch.